ArticleOncotarget2019

Contribution of trastuzumab to the prognostic improvement of HER2-positive early breast cancer in Spain: an estimation of life years and disease-free life years gained since its approval.

Eva Ciruelos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.